Melanie M Frigault Selected Research

ibrutinib

1/2021	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
1/2019	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Melanie M Frigault Research Topics

Disease

10	Neoplasms (Cancer) 09/2023 - 02/2005
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023 - 01/2019
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 06/2015
3	Disease Progression 01/2021 - 02/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2021 - 01/2021
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 10/2021
2	Headache (Headaches) 01/2021 - 01/2019
2	Diarrhea 01/2021 - 01/2019
2	Vomiting 01/2021 - 09/2017
2	Cough 01/2021 - 01/2019
2	Nausea 01/2021 - 09/2017
1	Lymphoma (Lymphomas) 11/2023
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Anemia 01/2022
1	Hyponatremia 01/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Neutropenia 01/2022
1	Abdominal Pain (Pain, Abdominal) 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021
1	Dizziness (Lightheadedness) 01/2021
1	Contusions 01/2021
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 02/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2020
1	Lymphocytosis 01/2020
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2019
1	Carcinogenesis 01/2019
1	Edema (Dropsy) 09/2017
1	Fatigue 09/2017
1	Trisomy (Trisomies) 06/2015

Drug/Important Bio-Agent (IBA)

8	acalabrutinibIBA 11/2021 - 01/2019
6	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023 - 01/2019
6	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2021 - 06/2015
3	Biomarkers (Surrogate Marker)IBA 09/2023 - 09/2017
2	Cyclin-Dependent Kinase 9IBA 11/2023 - 01/2022
2	ibrutinibIBA 01/2021 - 01/2019
2	Sunitinib (Sutent)FDA Link 01/2020 - 06/2015
2	Proto-Oncogene Proteins c-metIBA 01/2019 - 06/2015
1	RNA Polymerase II (RNA Polymerase B)IBA 11/2023
1	Transcription Factors (Transcription Factor)IBA 11/2023
1	CamptothecinIBA 09/2023
1	Leukocyte Elastase (Neutrophil Elastase)IBA 09/2023
1	IntegrinsIBA 09/2023
1	Pancreatic Elastase (Elastase)IBA 09/2023
1	Positive Transcriptional Elongation Factor BIBA 01/2023
1	Alkaline PhosphataseIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 11/2021
1	CytokinesIBA 11/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2021
1	vistusertibIBA 11/2021
1	tremelimumabIBA 11/2021
1	durvalumabIBA 11/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Gefitinib (Iressa)FDA Link 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	obinutuzumabIBA 01/2020
1	Immunoglobulin Variable RegionIBA 01/2020
1	CrizotinibIBA 06/2015
1	ElementsIBA 08/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2005

Therapy/Procedure

5	Therapeutics 01/2023 - 08/2014
1	Immunotherapy 11/2021
1	Drug Therapy (Chemotherapy) 08/2014